Form 4: Arcturus Therapeutics Executive Pad Chivukula Sells Shares Under 10b5-1 Plan

Pad Chivukula, Chief Scientific Officer & COO of Arcturus Therapeutics, sold 8,565 shares of common stock at an average price of $35.0075 on March 19, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 19, 2024, Pad Chivukula, the Chief Scientific Officer & COO of Arcturus Therapeutics Holdings Inc., sold 8,565 shares of the company's common stock.
• The sales were executed under a Rule 10b5-1 trading plan.
• The weighted average price for the shares sold was $35.0075, with individual sale prices ranging from $35.00 to $35.02 per share.
• Following the transaction, Chivukula directly owns 490,883 shares of Arcturus Therapeutics.
• The sale was reported on a Form 4 filing with the Securities and Exchange Commission.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting an executive's stock sale. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies. It is important to note that the sale was conducted under a pre-arranged 10b5-1 trading plan, which allows corporate insiders to sell shares at predetermined times and prices to avoid accusations of insider trading.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders, potentially causing a slight decrease in stock price due to increased selling pressure.

Key Dates